Medivation Announces Third Quarter Financial Results Teleconference and Webcast on November 9, 2011
November 02, 2011 07:00 ET
Medivation Announces Third Quarter Financial Results Teleconference and Webcast on November 9, 2011
SAN FRANCISCO, CA--(Marketwire - Nov 2, 2011) - Medivation, Inc. (
Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting the "Events and Presentations" page of the "Investor Relations" section of the Company's website at [ www.medivation.com ]. A replay also will be available for 30 days following the live presentation.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at [ www.medivation.com ].